Loading, Please Wait...
MIDDLETON, WI--(Marketwired - Jan 20, 2016) - PharmaSeek, an Investigative Site Network, has launched The Oncology Hub to provide sponsors and clinical research organizations (CROs) with a targeted, efficient approach to identify world-class clinical research institutions for oncology and inpatient studies. For institutions, this specialized network provides access to hundreds of studies each year in oncology and other therapeutic areas.
"Oncology and inpatient research make up over a third of all new studies, creating a unique challenge when it comes to site identification. It has become increasingly difficult to find new principal investigators (PIs) ready and willing to take on these types of studies. At the same time, research institutions are struggling to manage all of the connections they need to efficiently build their study pipelines," says Lindsay McCarthy, General Manager of The Oncology Hub. "The Oncology Hub serves as a matchmaker. Our seasoned business development team leverages our extensive database of sponsor and CRO contacts to make the most appropriate introductions to our network of research institutions."
The Oncology Hub is mutually beneficial to sponsors, CROs, and institutions. It provides sponsors and CROs with a targeted approach to reach high-quality research institutions specializing in specific indications, and study opportunities are posted in a centralized location to optimize feasibility and site selection. For institutions, The Oncology Hub maximizes exposure to over 100 clinical trial opportunities each year without requiring exclusivity. This allows institutions to keep pipelines full, increase revenues, and improve PI retention. In addition to providing access to many high-level trials, The Oncology Hub alerts institutions of these study opportunities in real time.
Once connections have been made, the study start-up process continues between the institution and sponsor or CRO. The two parties can then work together to evaluate the study protocol, negotiate budgets and contracts, and conduct the clinical trial.
"It's a simple model that solves a very real challenge for institutions, sponsors, and CROs," says McCarthy.